Navigation Links
Study Finds Discontinuation of Rosiglitazone Left Many Diabetes Patients Without Good Glycemic Control
Date:4/14/2009

JACKSONVILLE, Fla., April 14 /PRNewswire-USNewswire/ -- When concerns were raised about the safety of the diabetes medication, rosiglitazone, in May 2007, many patients and their doctors made the decision to discontinue use of the drug. A study published today in Endocrine Practice by Dr. Etta Fanning from the University of Texas Health Science Center along with her colleagues reported that many patients who discontinued use of rosiglitazone received less therapy and higher blood glucose levels as a result.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b)

A meta-analysis published in 2007 showed an increased risk of cardiovascular disease and myocardial infarction for patients using rosiglitazone. After that data was published, the FDA placed a black box warning on both thiazolidinediones (TZD) on the market, rosiglitazone and pioglitazone.

The study published in Endocrine Practice today entitled Clinical Practice Impact of Rosiglitazone Discontinuation on Glycemic Control shows that 89% of patients in the study group were using combination therapy before discontinuing use of rosiglitazone. After discontinuation, only 33% of patients were on a combination therapy. Another 13% of the group were not prescribed any diabetes medication at all.

The glycemic control of the group was also impacted after discontinuing rosiglitazone. In patients who received combination therapy, and who had laboratory values in both pre- and post-discontinuation periods, significant increases were observed in both fasting blood glucose and A1c.

In an accompanying Editorial, cardiologists Drs. Stuart Zarich and Dr. Richard Nesto, from Yale Medical School and Lahey Clinic, respectively, emphasized that patients who discontinue TZD's are at risk for higher fasting blood glucose and hemoglobin A1c levels, as reported by Fanning et al, which might further their cardiovascular risk. Furthermore, they point out that 5 large prospective studies have not found that rosiglitazone has any more cardiovascular risk than placebo or other hypoglycemic drugs and that a recent meta-analysis has also shown that TZD's do not increase cardiovascular mortality.

Resources

Link to April EP issue: http://aace.metapress.com/openurl.asp?genre=issue&issn=1530-891X&volume=15&issue=3

Link to Commentary:

http://media.aace.com/images/84/Fanning weissman.pdf

Link to Editorial:

http://media.aace.com/images/84/April Ep Editorial.pdf

About Endocrine Practice

Endocrine Practice, a peer-reviewed journal published seven times a year, is the official journal of the American College of Endocrinology (ACE) and the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists. More information about the journal can be found at www.endocrinepractice.org.

About the American Association of Clinical Endocrinologists (AACE)

AACE is a professional medical organization with more than 6,200 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE clinical endocrinologists advanced, specialized training enable them to be experts in the care of endocrine disease such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity. For further information about AACE, visit www.aace.com.


'/>"/>
SOURCE American Association of Clinical Endocrinologists
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study reports success in treating a rare retinal disorder
2. Low Blood Sugar Events Increase Dementia Risk in Elderly Patients With Type 2 Diabetes, Kaiser Permanente Study Finds
3. Avoiding No Mans Land: New Deloitte Study on Follow-on Biologics Investigates Proposed Legislation and Possible Unintended Consequences
4. Impotence Drugs Dont Harm Vision: Study
5. Three Medical Centers Awarded Funds to Study Generation of Cardiac Muscle Cells
6. National Physicians Study: Nearly One Third Would Choose Different Career Today
7. Ex-White House Drug Czar McCaffrey, U.S. Congress Drug Caucus Chair Cummings, CRC Health CEO Karlin Join Hopkins Researchers at News Conference April 17 on Breakthrough Study: Internet Video Drug Treatment as Effective as Traditional Counseling
8. Study of neighborhoods points to modifiable factors, not race, in cancer disparities
9. New alternative to biopsy detects subtle changes in cancer cells, Stanford study shows
10. Study Challenges Link Between Panic Attacks, PTSD
11. Study assesses new surgical procedure for regenerating cartilage in damaged knee joints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: